Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.
Mathews
V
V
Desire
S
S
George
B
B
Lakshmi
K M
KM
Rao
J G
JG
Viswabandya
A
A
Bajel
A
A
Srivastava
V M
VM
Srivastava
A
A
Chandy
M
M
D000328:Adult; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D012074:Remission Induction; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
D001152:Arsenicals; D010087:Oxides; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000077237:Arsenic Trioxide